|
1
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Harari PM: Epidermal growth factor
receptor inhibition strategies in oncology. Endocr Relat Cancer.
11:689–708. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Patel A, Unni N and Peng Y: The changing
paradigm for the treatment of HER2-positive breast cancer. Cancers
(Basel). 12(2081, 2081)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wuerstlein R and Harbeck N: Neoadjuvant
therapy for HER2-positive breast cancer. Rev Recent Clin Trials.
12:81–92. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Reis-Filho JS and Tutt AN: Triple negative
tumors: A critical review. Histopathology. 52:108–118.
2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Choi J, Jung WH and Koo JS:
Clinicopathologic features of molecular subtypes of triple negative
breast cancer based on immunohistochemical markers. Histol
Histopathol. 27:1481–1493. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Martin V, Botta F, Zanellato E, Molinari
F, Crippa S, Mazzucchelli L and Frattini M: Molecular
characterization of EGFR and EGFR-downstream pathways in triple
negative breast carcinomas with basal like features. Histol
Histopathol. 27:785–792. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng
JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, et al: The latest
battles between EGFR monoclonal antibodies and resistant tumor
cells. Front Oncol. 10(1249)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rosell R, Cardona AF, Arrieta O, Aguilar
A, Ito M, Pedraz C, Codony-Servat J and Santarpia M: Coregulation
of pathways in lung cancer patients with EGFR mutation: Therapeutic
opportunities. Br J Cancer. 1–10. 2021.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print).
|
|
12
|
Broekman F, Giovannetti E and Peters GJ:
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
World J Clin Oncol. 2:80–93. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tetsu O, Hangauer MJ, Phuchareon J, Eisele
DW and McCormick F: Drug resistance to EGFR inhibitors in lung
cancer. Chemotherapy. 61:223–325. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
He C, Li L, Guan X, Xiong L and Miao X:
Mutant p53 gain of function and chemoresistance: The role of mutant
p53 in response to clinical chemotherapy. Chemotherapy. 62:43–53.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baselga J, Albanell J, Ruiz A, Lluch A,
Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero
JM, et al: Phase II and tumor pharmacodynamic study of gefitinib in
patients with advanced breast cancer. J Clin Oncol. 23:5323–5333.
2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Green MD, Francis PA, Gebski V, Harvey V,
Karapetis C, Chan A, Snyder R, Fong A, Basser R and Forbes JF:
Australian New Zealand Breast Cancer Trials Group. Gefitinib
treatment in hormone-resistant and hormone receptor-negative
advanced breast cancer. Ann Oncol. 20:1813–1817. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Smith IE, Walsh G, Skene A, Llombart A,
Mayordomo JI, Detre S, Salter J, Clark E, Magill P and Dowsett M: A
phase II placebo-controlled trial of neoadjuvant anastrozole alone
or with gefitinib in early breast cancer. J Clin Oncol.
25:3816–3822. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Polychronis A, Sinnett HD, Hadjiminas D,
Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D,
Barrett N, et al: Preoperative gefitinib versus gefitinib and
anastrozole in postmenopausal patients with oestrogen-receptor
positive and epidermal-growth-factor-receptor-positive primary
breast cancer: A double-blind placebo-controlled phase II
randomised trial. Lancet Oncol. 6:383–391. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cristofanilli M, Valero V, Mangalik A,
Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C,
Bacus S, et al: Phase II, randomized trial to compare anastrozole
combined with gefitinib or placebo in postmenopausal women with
hormone receptor-positive metastatic breast cancer. Clin Cancer
Res. 16:1904–1914. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Carlson RW, O'Neill A, Vidaurre T, Gomez
HL, Badve SS and Sledge GW: A randomized trial of combination
anastrozole plus gefitinib and of combination fulvestrant plus
gefitinib in the treatment of postmenopausal women with hormone
receptor positive metastatic breast cancer. Breast Cancer Res
Treat. 133:1049–106. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen
MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E
and Ejlertsen B: Effect of adding gefitinib to neoadjuvant
chemotherapy in estrogen receptor negative early breast cancer in a
randomized phase II trial. Breast Cancer Res Treat. 126:463–470.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tryfonidis K, Basaran G, Bogaerts J,
Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D,
Cufer T, Piccart M, et al: A European organisation for research and
treatment of cancer randomized, double-blind, placebo-controlled,
multicentre phase II trial of anastrozole in combination with
gefitinib or placebo in hormone receptor-positive advanced breast
cancer (NCT00066378). Eur J Cancer. 53:144–154. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dickler MN, Cobleigh MA, Miller KD, Klein
PM and Winer EP: Efficacy and safety of erlotinib in patients with
locally advanced or metastatic breast cancer. Breast Cancer Res
Treat. 115:115–121. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lau YK, Du X, Rayannavar V, Hopkins B,
Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, et al:
Metformin and erlotinib synergize to inhibit basal breast cancer.
Oncotarget. 5:10503–10517. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ueno NT and Zhang D: Targeting EGFR in
triple negative breast cancer. J Cancer. 2:324–228. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Guix M, Granja Nde M, Meszoely I, Adkins
TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer
IA, et al: Short preoperative treatment with erlotinib inhibits
tumor cell proliferation in hormone receptor-positive breast
cancers. J Clin Oncol. 26:897–906. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Harbeck N, Huang CS, Hurvitz S, Yeh DC,
Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, et al: Afatinib
plus vinorelbine versus trastuzumab plus vinorelbine in patients
with HER2-overexpressing metastatic breast cancer who had
progressed on one previous trastuzumab treatment (LUX-Breast 1): An
open-label, randomised, phase 3 trial. Lancet Oncol. 17:357–366.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cortés J, Dieras V, Ro J, Barriere J,
Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A,
et al: Afatinib alone or afatinib plus vinorelbine versus
investigator's choice of treatment for HER2-positive breast cancer
with progressive brain metastases after trastuzumab, lapatinib, or
both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2
trial. Lancet Oncol. 16:1700–1710. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kawaguchi Y, Hanaoka J, Hayashi H,
Mizusaki N, Iihara H, Itoh Y and Sugiyama T: Clinical efficacy of
afatinib treatment for a patient with leptomeningeal
carcinomatosis. Chemotherapy. 62:147–150. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hanusch C, Schneeweiss A, Loibl S, Untch
M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B,
et al: Dual blockade with afatinib and trastuzumab as NEoadjuvant
treatment for patients with locally advanced or operable breast
cancer receiving taxane-anthracycline containing chemotherapy-DAFNE
(GBG-70). Clin Cancer Res. 21:2924–291. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen ZL, Shen YW, Li ST, Li CL, Zhang LX
and Yang J, Lv M, Lin YY, Wang X and Yang J: The efficiency and
safety of trastuzumab and lapatinib added to neoadjuvant
chemotherapy in Her2-positive breast cancer patients: A randomized
meta-analysis. Onco Targets Ther. 9:3233–3247. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Baselga J, Bradbury I, Eidtmann H, Di
Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van
Dooren V, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): A randomised, open-label, multicentre,
phase 3 trial. Lancet. 379:633–640. 2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
de Azambuja E, Holmes AP, Piccart-Gebhart
M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I,
Smith I, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): Survival outcomes of a randomised,
open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 15:1137–1146.
2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bonnefoi H, Jacot W, Saghatchian M,
Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A,
Quenel-Tueux N, et al: Neoadjuvant treatment with docetaxel plus
lapatinib, trastuzumab, or both followed by an anthracycline-based
chemotherapy in HER2-positive breast cancer: Results of the
randomised phase II EORTC 10054 study. Ann Oncol. 26:325–332.
2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Piccart-Gebhart M, Holmes E, Baselga J, de
Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A,
Pritchard KI, et al: Adjuvant lapatinib and trastuzumab for early
human epidermal growth factor receptor 2-positive breast cancer:
Results from the randomized phase III adjuvant lapatinib and/or
trastuzumab treatment optimization trial. J Clin Oncol.
34:1034–1042. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer. N Engl J Med. 355:2733–2743.
2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Schwartzberg LS, Franco SX, Florance A,
O'Rourke L, Maltzman J and Johnston S: Lapatinib plus letrozole as
first-line therapy for HER-2+ hormone receptor-positive metastatic
breast cancer. Oncologist. 15:122–129. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sherrill B, Amonkar MM, Sherif B, Maltzman
J, O'Rourke L and Johnston S: Quality of life in hormone
receptor-positive HER-2+ metastatic breast cancer patients during
treatment with letrozole alone or in combination with lapatinib.
Oncologist. 15:944–953. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Johnston S, Pippen J Jr, Pivot X,
Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A,
Kennedy MJ, et al: Lapatinib combined with letrozole versus
letrozole and placebo as first-line therapy for postmenopausal
hormone receptor-positive metastatic breast cancer. J Clin Oncol.
27:5538–5546. 2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Blackwell KL, Burstein HJ, Storniolo AM,
Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff
J, et al: Randomized study of lapatinib alone or in combination
with trastuzumab in women with ErbB2-positive,
trastuzumab-refractory metastatic breast cancer. J Clin Oncol.
28:1124–1130. 2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
National Comprehensive Cancer Network.
NCCN clinical practice guidelines in oncology (NCCN
Guidelines®): Breast cancer version 2.2016, 2016.
|
|
42
|
Chow LW, Xu B, Gupta S, Freyman A, Zhao Y,
Abbas R, Vo Van ML and Bondarenko I: Combination neratinib
(HKI-272) and paclitaxel therapy in patients with HER2-positive
metastatic breast cancer. Br J Cancer. 108:1985–1993.
2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chan A, Delaloge S, Holmes FA, Moy B,
Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz
G, et al: Neratinib after trastuzumab-based adjuvant therapy in
patients with HER2-positive breast cancer (ExteNET): A multicentre,
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 17:367–377. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rixe O, Franco SX, Yardley DA, Johnston
SR, Martin M, Arun BK, Letrent SP and Rugo HS: A randomized, phase
II, dose-finding study of the pan-ErbB receptor tyrosine-kinase
inhibitor CI-1033 in patients with pretreated metastatic breast
cancer. Cancer Chemother Pharmacol. 64:1139–1148. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Murthy R, Borges VF, Conlin A, Chaves J,
Chamberlain M, Gray T, Vo A and Hamilton E: Tucatinib with
capecitabine and trastuzumab in advanced HER2-positive metastatic
breast cancer with and without brain metastases: A non-randomised,
open-label, phase 1b study. Lancet Oncol. 19:880–888.
2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Murthy RK, Loi S, Okines A, Paplomata E,
Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et
al: Tucatinib, trastuzumab, and capecitabine for HER2-positive
metastatic breast cancer. N Engl J Med. 382:597–609.
2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J,
Luo Y, Xing P, Lan B, Li M, et al: Phase I study and biomarker
analysis of pyrotinib, a novel irreversible pan-ErbB receptor
tyrosine kinase inhibitor, in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer. J Clin Oncol.
35:3105–3112. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zhang K, Hong R, Kaping L, Xu F, Xia W,
Qin G, Zheng Q, Lu Q, Zhai Q, Shi Y, et al: CDK4/6 inhibitor
palbociclib enhances the effect of pyrotinib in HER2-positive
breast cancer. Cancer Lett. 447:130–140. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Xuhong JC, Qi XW, Zhang Y and Jiang J:
Mechanism, safety and efficacy of three tyrosine kinase inhibitors
lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Am J Cancer Res. 9:2103–2119. 2019.PubMed/NCBI
|
|
50
|
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu
Y, Li H, Yu S, Feng J, Wang S, et al: Pyrotinib or lapatinib
combined with capecitabine in HER2-positive metastatic breast
cancer with prior taxanes, anthracyclines, and/or trastuzumab: A
randomized, phase II study. J Clin Oncol. 37:2610–2619.
2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jiang Z, Yan M, Hu X, Zhang Q, Ouyang Q,
Feng J, Yin Y, Sun T, Tong Z, Wang X, et al: Pyrotinib combined
with capecitabine in women with HER2+ metastatic breast cancer
previously treated with trastuzumab and taxanes: A randomized phase
III study. J Clin Oncol. 37 (Suppl 15)(S1001)2019.
|
|
52
|
He L, Zhang F, Ma Y, Zuo L and Xu Y:
Pathological complete response from pyrotinib combined with
trastuzumab, paclitaxel and cisplatin in a postpartum woman with
HER2-positive locally advanced breast cancer: A case report. Onco
Targets Ther. 13:8749–8756. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang C, Lin Y, Zhou Y, Mao F, Zhu H, Guan
J, Zhang X, Shen S, Huang X, Chen C, et al: Pyrotinib with
trastuzumab and aromatase inhibitors as first-line treatment for
HER2 positive and hormone receptor positive metastatic or locally
advanced breast cancer: Study protocol of a randomized controlled
trial. BMC Cancer. 20(653)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Goozner M: Avastin hearing leads to more
uncertainty over drug's future. J Natl Cancer Inst. 103:1148–1150.
2011.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Barton-Burke M, Ciccolini K, Mekas M and
Burke S: Dermatologic reactions to targeted therapy: A focus on
epidermal growth factor receptor inhibitors and nursing care. Nurs
Clin North Am. 52:83–113. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Melosky B and Hirsh V: Management of
common toxicities in metastatic NSCLC related to anti-lung cancer
therapies with EGFR-TKIs. Front Oncol. 4(238)2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Wacker B, Nagrani T, Weinberg J, Witt K,
Clark G and Cagnoni PJ: Correlation between development of rash and
efficacy in patients treated with the epidermal growth factor
receptor tyrosine kinase inhibitor erlotinib in two large phase III
studies. Clin Cancer Res. 13:3913–3921. 2007.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Nowsheen S, Cooper T, Stanley JA and Yang
ES: Synthetic lethal interactions between EGFR and PARP inhibition
in human triple negative breast cancer cells. PLoS One.
7(e46614)2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
García-Parra J, Dalmases A, Morancho B,
Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles
P, et al: Poly (ADP-ribose) polymerase inhibition enhances
trastuzumab antitumour activity in HER2 overexpressing breast
cancer. Eur J Cancer. 50:2725–2734. 2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Stagg J, Loi S, Divisekera U, Ngiow SF,
Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy
requires type I and II interferons and synergizes with anti-PD-1 or
anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 108:7142–7147.
2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ménard S, Balsari A, Casalini P, Tagliabue
E, Campiglio M, Bufalino R and Cascinelli N: HER-2-positive breast
carcinomas as a particular subset with peculiar clinical behaviors.
Clin Cancer Res. 8:520–525. 2002.PubMed/NCBI
|
|
63
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Hoeijmakers JH: Genome maintenance
mechanisms for preventing cancer. Nature. 411:366–374.
2001.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lee MJ, Ye AS, Gardino AK, Heijink AM,
Sorger PK, MacBeath G and Yaffe MB: Sequential application of
anticancer drugs enhances cell death by rewiring apoptotic
signaling networks. Cell. 149:780–794. 2012.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Dawood S, Merajver SD, Viens P, Vermeulen
PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A,
Krishnamurthy S, et al: International expert panel on inflammatory
breast cancer: Consensus statement for standardized diagnosis and
treatment. Ann Oncol. 22:515–523. 2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Zell JA, Tsang WY, Taylor TH, Mehta RS and
Anton-Culver H: Prognostic impact of human epidermal growth
factor-like receptor 2 and hormone receptor status in inflammatory
breast cancer (IBC): Analysis of 2,014 IBC patient cases from the
California cancer registry. Breast Cancer Res.
11(R9)2009.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016.PubMed/NCBI View Article : Google Scholar
|
